Monash University Secures $22.4M for Lymphatic Pumping Research with ARPA-H
Monash University, in partnership with the University of Missouri and the University of Pennsylvania, has secured up to $22.4 million AUD from ARPA-H to develop innovative medicines aimed at reversing poor lymphatic vessel function. This research is part of the GLIDE program, focusing on treating primary lymphatic diseases and chronic conditions by restoring lymphatic pumping using novel allosteric drug mechanisms. The five-year initiative involves a multidisciplinary team and targets conditions like lymphedema and rheumatoid arthritis.
Theia Market Signal Identification - AI Assisted
Monash University, alongside the University of Missouri and the University of Pennsylvania, has received up to $22.4 million AUD from ARPA-H to advance research in lymphatic pumping. This initiative, part of the GLIDE program, aims to develop oral medicines that restore lymphatic function using allosteric mechanisms.
The five-year project, led by researchers at the Monash Institute of Pharmaceutical Sciences, targets diseases such as lymphedema and rheumatoid arthritis, addressing a significant unmet medical need. The team will design drugs that interact with specific receptor proteins on lymphatic vessels, aiming for safer and more effective treatments.
Comments